- Home
- GLTO vs PRPH Comparison
GLTO vs PRPH Comparison
Compare GLTO & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- PRPH
- Stock Information
- Founded
- GLTO 2011
- PRPH 1989
- Country
- GLTO Denmark
- PRPH United States
- Employees
- GLTO N/A
- PRPH N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- PRPH Health Care
- Exchange
- GLTO Nasdaq
- PRPH Nasdaq
- Market Cap
- GLTO 23.7M
- PRPH 21.9M
- IPO Year
- GLTO 2020
- PRPH 1997
- Fundamental
- Price
- GLTO $10.99
- PRPH $0.49
- Analyst Decision
- GLTO Buy
- PRPH
- Analyst Count
- GLTO 1
- PRPH 0
- Target Price
- GLTO $10.00
- PRPH N/A
- AVG Volume (30 Days)
- GLTO 7.6M
- PRPH 1.5M
- Earning Date
- GLTO 10-31-2025
- PRPH 11-12-2025
- Dividend Yield
- GLTO N/A
- PRPH N/A
- EPS Growth
- GLTO N/A
- PRPH N/A
- EPS
- GLTO N/A
- PRPH N/A
- Revenue
- GLTO N/A
- PRPH $5,588,000.00
- Revenue This Year
- GLTO N/A
- PRPH $221.82
- Revenue Next Year
- GLTO N/A
- PRPH N/A
- P/E Ratio
- GLTO N/A
- PRPH N/A
- Revenue Growth
- GLTO N/A
- PRPH N/A
- 52 Week Low
- GLTO $2.01
- PRPH $0.22
- 52 Week High
- GLTO $31.70
- PRPH $2.50
- Technical
- Relative Strength Index (RSI)
- GLTO 58.62
- PRPH 52.35
- Support Level
- GLTO $10.53
- PRPH $0.45
- Resistance Level
- GLTO $18.45
- PRPH $0.54
- Average True Range (ATR)
- GLTO 2.35
- PRPH 0.06
- MACD
- GLTO 0.43
- PRPH -0.01
- Stochastic Oscillator
- GLTO 26.56
- PRPH 27.37
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.